A patient with moderate persistent asthma should be managed with which daily treatment?

For a patient with moderate persistent asthma, the recommended management involves a combination of daily inhaled corticosteroids and long-acting bronchodilators. This approach is supported by guidelines that emphasize achieving better asthma control through the use of multiple treatments.

Inhaled corticosteroids are essential for reducing inflammation and controlling the underlying airway hyperreactivity. When used alone, they provide a solid foundation for managing asthma symptoms. However, for patients who experience persistent symptoms despite using inhaled steroids, adding a long-acting beta-agonist (LABA) is crucial. The LABA works by providing bronchodilation, helping to open the airways and improve airflow, thereby enhancing overall control of asthma and reducing the frequency of exacerbations.

This combination therapy is effective because it addresses different aspects of asthma pathophysiology—controlling inflammation with corticosteroids and achieving bronchodilation with LABAs. Consequently, this regimen is designed to improve overall lung function and quality of life for patients with moderate persistent asthma.

Other options are less effective on their own. For instance, relying solely on inhaled steroids might not adequately address the patient's breathing difficulties. Long-acting bronchodilators alone do not reduce the underlying inflammation; thus, they are not sufficient as a standalone